{"262": "MTCT", "276": "maternal viral load .29 000 copies/ml", "278": "", "316": "", "305": "", "306": "increases risk of transmission", "307": "", "277": "15-45", "312": "impaired placental DC-SIGNR expression increases risk of transmission", "318": "promotes pathogen elimination by opsonization and phagocytosis", "321": "", "568": "interferon-induced transmembrane", "569": "three", "570": "2BP", "571": "IFITM5 with FKBP11", "572": "immune system activity", "573": "S-palmitoylation on the protein", "574": "bonerestricted IFITM-like (BRIL) protein", "575": "because the region upstream of the ifitm5 gene lacks the interferon regulatory elements", "576": "65%", "577": "65%", "580": "aspartate", "917": "", "918": "single-stranded, linear, and nonsegmented RNA", "919": "", "920": "", "921": "5=", "1658": "HCoV", "1659": "HCoV-OC43", "1660": "HCoV-OC43", "1717": "Highly virulent species of HCoV", "1718": "14% to 45%.", "1719": "HCoV-OC43", "1720": "HCoV-HKU1", "1612": "Intranasal entry", "1615": "highly vascularized", "1616": "Metered dose inhalers (MDIs) and dry powder inhalers (DPIs)", "1617": "", "1618": "Intranasal entry", "1619": "respiratory bronchioles, alveolar ducts, and alveolar sacs", "1620": "between 1-5 \u03bcm", "1621": "be stable, enter the target cells, and be present in the cytoplasm at sufficient concentration", "1622": "27.6 kb", "1623": "10", "1624": "SC021202", "257": "7.3 billion", "248": "Middle East respiratory syndrome coronavirus", "249": "Transmissibility and severity", "250": "January 30, 2020", "251": "H7N9", "252": "", "253": "20% to 30%", "254": "20%", "255": "", "1657": "35\u202f000 to 60\u202f000", "550": "RSV or HRV", "553": "there are no approved vaccines or medications available", "544": "Gammaproteobacteria", "545": "antibiotic-resistant bacteria", "327": "influenza and parainfluenza viruses, RSV, adenovirus, rhinovirus, human metapneumovirus, enterovirus, bocavirus and coronavirus", "465": "facilitate pathogen clearance", "467": "Dysregulation of the antibody response", "474": "hybridoma technology", "476": "somatic rearrangement", "478": "vaccine design", "485": "", "489": "increased our mechanistic understanding of the humoral immune response", "490": "In vivo methods to probe antigen-specific B cell responses in the presence of other antigen-presenting cells and T cell helpers, have increased our mechanistic understanding of the humoral immune response", "494": "", "497": "advanced our understanding", "557": "2012", "558": "21%", "559": "47.7%", "560": "Dromedary camels", "562": "11-13 days", "563": "16 days", "564": "", "565": "between 41 and 60 years", "1631": "They have demonstrated higher susceptibility to a wider variety of human pathogens", "1632": "", "1633": "it promotes cytokine production, the induction of cell surface co-stimulatory molecules, and facilitates the cross-presentation of antigen", "1634": "it promotes germinal center formation", "567": "differences from the average codon usage frequencies", "566": "Mutational bias", "328": "pneumonia", "329": "bronchitis, pneumonia and bronchiolitis", "330": "NK cells", "331": "", "332": "", "1592": "June 30, 2017", "1593": "to promote, set standards in, and evaluate progress toward better health for people in all countries", "1595": "a lowincome or middle-income country", "1596": "proven leader and advocate", "502": "", "504": "The pneumococcal conjugate vaccination and Haemophilus influenzae type B conjugate vaccination", "507": "", "510": "", "511": "The overall burden of childhood pneumonia has been reduced substantially over the last decade", "512": "25%", "513": "", "514": "81%", "515": "", "516": "lead to significant morbidity and chronic disease", "517": "", "518": "Chest radiologic changes", "519": "a dense or fluffy opacity that occupies a portion or whole of a lobe, or the entire lung", "520": "pneumococcal conjugate vaccination and Haemophilus influenzae type B conjugate vaccination", "521": "18%", "522": "presumed bacterial pneumonia", "524": "", "530": "pneumococcal serotypes not included in pneumococcal conjugate vaccination-7", "532": "substantial reduction in pediatric empyema following pneumococcal conjugate vaccination-13 introduction", "533": "ambulatory pneumonia", "534": "", "535": "low transplacental anti-pertussis immunoglobulin G levels", "536": "childhood tuberculosis is a major cause of morbidity and mortality in many low-and middle-income countries", "537": "HIV infection", "538": "increases odds of pneumonia by 1.6 times", "539": "HIV infection", "540": "68%.", "541": "Influenza vaccination during pregnancy is safe", "923": "a rare complication of pneumonia", "1625": "an enveloped, positive-stranded RNA virus that preferentially replicates in hepatocytes", "1626": "At least 170 million", "1627": "cirrhosis and hepatocellular carcinoma", "1628": "pegylated alpha-interferon and ribavirin", "2129": "Calf septicemia", "2131": "human urine", "2130": "a low molecular weight, antimicrobial peptide hormone", "2132": "the liver", "2133": "", "2134": "Fe", "2135": "", "2136": "Fe is a significant nutritional source", "2137": "Fe absorption", "2138": "", "2139": "Free iron", "2140": "superoxide dismutase", "1635": "various biological processes", "593": "faecal oocyst count reduction test", "595": "oocyst excretion", "581": "a rare, sudden onset of unilateral chorioretinopathy", "582": "", "583": "herpes simplex virus (HSV) I-II, varicella zoster virus (VZV), West Nile virus, coxsackievirus, echovirus (subgroup of enterovirus), and corona virus", "584": "Serologic testing", "1597": "parainfluenza virus 4, respiratory syncytial virus B and enterovirus", "1598": "Coronavirus OC43", "1599": "2-5 times higher", "1600": "the continent of Africa", "1601": "age, sex, overcrowding, nutritional status, socio-economic status, and where study of ARIs is currently limited", "1602": "mild illness", "1603": "Coronavirus OC43", "1604": "13.3%,", "1605": "12.5%", "1606": "p < 0.001", "1607": "community-based participatory disease surveillance methods", "1608": "RTIs are a major cause of morbidity and mortality worldwide", "1609": "two to three times", "1610": "acute RTIs", "1611": "Illnesses", "1613": "winter and early spring months", "1614": "RSV and rhinovirus", "1629": "RSV", "1630": "13%", "2125": "544 base pairs", "2126": "Irish ECoVs had a 148-nucleotide insertion", "2127": "high level of homology", "2128": "among adult riding, racing and show horses", "2167": "acellular", "2168": "Southeast Asia", "2169": "whole cell", "2170": "cough and wheeze", "2171": "nasal swabs", "2173": "every 2 to 4 years", "2174": "requires a minimum of 2 weeks of cough, whoop, or posttussive vomiting", "2175": "weekly proportion of laboratory tests that are positive for influenza", "2176": "additional irregularities were noticed in the laboratory data", "2177": "influenza A, influenza B, RSV, adenovirus and PIV", "585": "higher HPAI H5N1 emergence risk", "586": "", "587": "landscapes where intensive and extensive forms of poultry production overlap were found at greater risk", "588": "disease emergence is driven by the co-incidence of genetic, physical environmental, ecological, and social factors", "590": "a 'space' oriented approach that accounts for the effects of physical proximity", "591": "insensitivity to co-linearity and non-linear responses", "592": "higher HPAI H5N1 emergence risk", "589": "peri-urban landscapes", "594": "", "596": "higher levels of chicken densities, duck and geese flock size diversities, and fraction of land under rice or aquaculture than rural and urban areas", "597": "water bodies offer routes for transmission and persistence of the virus", "598": "Proximity to water bodies increases the risk of outbreaks", "599": "poultry population fell 15%.", "600": "", "655": "", "651": "", "658": "", "661": "inhibiting virus entry", "662": "", "924": "a family of AAA-ATPase proteins", "926": "microtubule severing enzyme genes SPG4", "927": "missense", "928": "KATNAL2", "929": "Katanin p60 subunit A-like 1", "930": "central nervous system", "931": "Ciliary beat frequency and pattern", "932": "circadian rhythms, sleep and behaviour", "1220": "arthropod-borne flavivirus", "1222": "calcium", "1223": "transmembrane domain 3", "1224": "voltage-gated Ca(2+) channel (VGCC) inhibitor", "1225": "over 70", "1226": "", "1227": "single", "1228": "capsid (C), membrane (premembrane [prM] and membrane [M] ), and envelope (E),", "1229": "viral replication, virion assembly, and virus escape from immune surveillance", "1230": "Recombinant viral particles", "1231": "high-throughput screening", "1232": "equal to the 50% cytotoxic concentration [CC 50 [/50% inhibitory concentration [IC 50", "1233": "JEV structural proteins", "1234": "JEV", "430": "nine", "431": "double-stranded", "432": "VP1-VP4, VP6 and VP7", "433": "NSP1-NSP5/NSP6", "434": "real-time polymerase chain reaction", "634": "early identification of outbreak", "642": "", "644": "suspending elective surgeries, canceling ambulatory clinics and outpatient diagnostic procedures, transferring patients to other institutions, and restricting hospital visitors", "645": "highly contagious with multiple transmission route, high exposure dose, long daily contact hours, and ICU stay", "669": "", "1935": "Pseudorabies (PRV) and Rabies viruses", "1936": "anterograde", "1937": "method of delivery of the G gene", "1938": "Pseudorabies (PRV) and Rabies viruses", "2141": "a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections", "2142": "viral upper respiratory tract infections", "2143": "48 hpi or 72 hpi", "2144": "more than 175 deaths", "2145": "400", "2146": "had contact with poultry or visited live animal markets", "2147": "some sporadic cases seemed to be a result of human to human transmissions", "2148": "pneumonia", "2149": "three to five million", "2150": "250,000 to 500,000", "2151": "Since the majority of influenza infections causes uncomplicated illnesses", "2153": "54.5-83.3%", "2154": "respiratory viral infection", "2155": "interference with viral attachment", "2156": "in combination they could complement each other to provide protection against a broader spectrum of influenza virus strains", "2157": "a clinically proven and marketed compound for the treatment of viral upper respiratory tract infections", "2158": "decreased probability to develop complications", "2159": "3.3 days faster recovery from symptoms", "2160": "reduction", "2163": "antiviral efficacy", "2164": "Intranasal therapy with carrageenan and Zanamivir starting 72 hpi significantly protects lethally influenza H1N1(09)pdm infected mice", "2165": "H7N7 required much higher concentrations of carrageenan and Zanamivir, respectively, to achieve similar inhibition efficiencies", "2166": "Zanamivir is directly applied as active drug and can also be administered intranasally", "2179": "IC 50 values varied widely depending on the influenza virus strain", "2180": "H7N7 required much higher concentrations of carrageenan and Zanamivir, respectively, to achieve similar inhibition efficiencies", "2182": "inhibitor of hRV [36] and influenza A [37] replication", "809": "Poxviruses", "798": "pre-existing immune responses in the host", "800": "detrimental", "802": "Salmonella serovars and Listeria spp", "804": "E. coli and lactic acid bacteria", "805": "E. coli is a commensal and lactic acid bacteria are present in most fermented food items and are therefore naturally present in the host", "812": "Gram-positive intracellular food-borne pathogens", "813": "it can invade a variety of cells", "817": "Salmonella and adenovirus", "825": "YFV", "831": "LAB and E. coli", "872": "Both vertical and horizontal transmission is associated with Salmonella in chickens", "833": "large DNA-packing capacity and their thermal and genetic stability", "836": "ease of production, safety profile, genetic stability, the ease of DNA genome manipulation, and the ability to stimulate both innate and adaptive immune responses and induce both T and B cell responses", "838": "large DNA-packing capacity and their thermal and genetic stability", "841": "large DNA-packing capacity and their thermal and genetic stability", "845": "large DNA-packing capacity and their thermal and genetic stability", "858": "strong CTL immune responses", "864": "strong CTL immune responses", "861": "strong CTL immune responses", "870": "", "874": "reduction in the subsequent immune response", "875": "reduction in the subsequent immune response", "876": "strong CTL immune responses", "877": "use of vectors derived from nonhuman", "878": "masking the Ad vector inside dendritic cells", "879": "almost always resulted in a reduction in the subsequent immune response", "880": "avoiding pre-existing vector immunity", "601": "by fecal\u2013oral contact", "602": "to induce mucosal immune responses", "603": "villous epithelial cells", "604": "mucosal", "605": "gastric acid and pepsin", "606": "nonpathogenic Gram-positive bacterium", "607": "maintenance of gut homeostasis by dendritic cells (DCs) [17] . DCs are the most important professional antigen-presenting cells", "608": "gut-associated lymphoid tissue", "609": "PPs", "610": "Intestinal IELs", "611": "serum IgG and mucosal SIgA", "612": "The area of PPs", "613": "", "1197": "", "1199": "", "1201": "2002", "1202": "31 December", "1203": "", "1204": "", "1205": "", "1206": "", "1207": "", "1208": "public health, science and politics", "1209": "2012", "1210": "less than 2 weeks", "1211": "", "1212": "", "1213": "the volume and diversity of the information available and the relative lack of verification mechanisms", "1214": "", "1215": "", "1216": "around 3", "1217": "a case infected significantly more contacts than the average", "1218": "up to 5 m", "1939": "Between 3-5 million", "1940": "over 250 000", "1941": "53%.", "1942": "ATII cells", "1944": "four", "1945": "epithelial and endothelial cells", "1946": "transmembrane domain", "1947": "CEACAM1-4L and CEACAM1-3L", "1948": "heterophilically", "1949": "tyrosine phosphatase", "1950": "Recognition of intracellular viral RNA by pattern recognition receptors (PRRs)", "1951": "", "1952": "recognizing and killing infected cells", "1953": "modification of influenza hemagglutinin (HA) glycosylation", "641": "planning and conducting safe patient transport", "900": "two to three million", "901": "60%", "902": "Rotavirus infection", "903": "40 and 41", "904": "1907", "905": "1. Universal primer-PCR [41] ; 2. Random priming-based PCR [42] ; 3. Virus Discovery cDNA, Amplified Fragment Length Polymorphism (VIDISCA) [43] ; and 4. Sequence-Independent Single Primer Amplification (SISPA)", "906": "virus discovery technique", "907": "", "908": "", "909": "after being fully isolated from the body and repeatedly grown in pure culture, the microbe can induce the disease anew", "911": "after being fully isolated from the body and repeatedly grown in pure culture, the microbe can induce the disease anew", "912": "not applicable", "1721": "studies of protein\u2013protein interactions", "1722": "unanticipated ability of the phage to penetrate into brain tissue", "1723": "high immunogenicity, relative antigenic simplicity and ability to activate a range of immune responses", "1724": "prophylactic and therapeutic agent", "1725": "bioconjugation and surface chemistry applications", "1726": "large population sizes and fast generation times", "1727": "", "1728": "bioengineering", "1730": "", "1731": "magnetics, optics, and electronics", "1732": "unique biological, immunological, and physicochemical properties of the phage", "1733": "its ability to display polypeptides on the virion's surface", "1734": "maximum tolerated size of the fused polypeptide, its copy number on the phage, and potentially, the structure of the displayed polypeptide", "1735": "by fusing DNA encoding a polypeptide of interest directly to the gene encoding a coat protein within the phage genome", "1736": "tumor-targeting moieties", "1737": "a diverse pool of recombinant filamentous phage displaying an array of polypeptide variants", "1738": "do not use F-pili for entry", "1739": "using the phage as carrier to elicit antibodies against poorly immunogenic haptens or polypeptide", "1740": "low cost of production", "1741": "the maximum tolerated size of the fused polypeptide", "1742": "in many cases, peptides incompletely or inadequately mimic epitopes on folded proteins", "1743": "filamentous phage virion", "1744": "HIV-1 gp120, gp41, gag, and reverse transcriptase", "1745": "HIV-1 gp120, gp41, gag, and reverse transcriptase", "1747": "copy number differences", "1748": "protein engineering", "1749": "immunogenic without adjuvant", "1750": "serum antibody titers against the phage typically reach 1:10 5 -1:10 6 after 2-3 immunizations, and are maintained for at least 1", "1751": "IgM and IgG2b isotypes in C57BL/6 mice", "1752": "through multiple mechanisms", "1753": "MyD88 signaling", "1754": "it is cleared from the blood within hours", "1755": "speed, ease of purification and low cost of production", "1756": "preservation of biodiversity of other organisms in at-risk ecosystems", "1757": "M13 or fd phage", "1758": "M13 phage loaded with doxorubicin and displaying a targeting peptide on pIII", "1759": "delayed tumor growth", "1760": "unanticipated ability of the phage to penetrate into brain tissue", "1761": "rod-like protein capsid", "1762": "The regularity of the phage pVIII lattice and its diversity of chemically addressable groups", "1763": "", "1764": "", "1765": "pVIII monomers", "1766": "unique structural and biological properties", "913": "a Gram positive, anaerobic bacterium that can form highly resistant endospores", "914": "an adaptive strategy that enables bacteria to survive harsh environmental conditions for prolonged periods of time", "915": "Spo0A", "916": "clostridial toxins A and B", "941": "Western blot analysis", "933": "arthropod-borne virus", "934": "acute and fatal encephalitis", "935": "35%", "936": "10%", "937": "PARP12L", "938": "host-pathogen dynamics", "939": "endoplasmic reticulum (ER) stress", "940": "inositolrequiring enzyme 1 (IRE1), protein kinase RNA-like ER kinase (PERK), and activating transcription factor 6 (ATF6) (33, 34)", "942": "the nuclei", "943": "Hs00152928_m1", "1249": "the ability of a given host to tolerate an infection, and to return to a state of health", "1250": "coronaviruses", "1251": "betacoronavirus", "1252": "2003", "1253": "about 8000", "1256": "35-50%", "1255": "10%", "1258": "double membrane vesicles (DMVs),", "1260": "severe lung pathology", "1262": "", "1263": "rapid progression to ARDS, however, there are some distinct differences in the infectivity and pathogenicity", "1265": "a successful host must not only be able to clear the pathogen, but tolerate damage caused by the pathogen itself and also by the host's immune response", "1266": "prevents sensing of its genome", "1267": "more rapidly between hosts", "1268": "more rapidly between hosts", "1269": "double membrane vesicles", "1270": "rapid progression to ARDS", "1272": "delayed", "1271": "suppress the type I IFN response, and other aspects of innate antiviral immunity", "1273": "decrease mortality", "1274": "antiviral type I", "1275": "increased pathogen burden, and thus increase virus-induced pathology", "1276": "protect against inflammation-induced death", "1277": "", "1278": "They act to stabilize the activation of aspects of the innate immune response and prevent excessive inflammation", "1279": "", "1280": "higher neutrophil count and low T-cell counts", "1281": "MERS-CoV has been more easily contained", "1282": "Host resilience is the ability of a host to tolerate the effects of an infection and return to a state of health", "1283": "Clinical studies have started to correlate specific biomarkers with disease outcomes in ARDS patients", "325": "engineered, non-lytic, filamentous bacteriophages", "326": "identification of peptide ligands by receptors, the mapping of substrate sites for enzymes, and the creation of antibody peptide libraries", "279": "NLRP3", "280": "caspase-1", "281": "SARS-CoV viroporin 3a", "282": "transmembrane pore-forming viral proteins", "283": "Betacoronavirus", "284": "Coronaviridae", "285": "an enveloped virus", "287": "", "288": "", "289": "9.6%,", "290": "tumor necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2, and IL-6", "292": "by sensing the cellular damage or distress induced by viroporins", "293": "76", "294": "Ca 2+ -permeable", "296": "NLRP3 inflammasome", "887": "TNF-\u03b1", "888": "", "889": "MKP-1", "890": "Mycobacterium tuberculosis", "891": "one third", "892": "9.2 million", "893": "extracellular signal-regulated kinase 1 and 2 (ERK1/2), p38 MAPK, and c-Jun N-terminal kinase (JNK)", "894": "by phosphorylation", "895": "", "896": "at least 10", "897": "a cell wall component of Gram-negative bacteria", "898": "a Gram positive bacteria", "899": "MAPK", "1241": "Constant evolution of circulating influenza virus strains and the emergence of new strains", "1242": "pox-vectored influenza virus vaccines", "1243": "Recombinant live-attenuated or replication-deficient influenza viruses", "1244": "native expression of influenza antigens", "1245": "virus vectors enable native expression of influenza antigens", "1246": "preexisting immunity", "1247": "trivalent inactivated influenza vaccine (TIV), quadrivalent influenza vaccine (QIV), and live attenuated influenza vaccine (LAIV; in trivalent and quadrivalent forms).", "1248": "whole virus inactivated, split virus inactivated, and subunit vaccines", "1254": "", "1257": "intramuscularly", "1259": "three or four inactivated viruses", "1261": "by induction of humoral responses to the hemagglutinin (HA) protein, the major surface and attachment glycoprotein on influenza", "1264": "hemagglutinin", "1472": "by the hemagglutination-inhibition (HI) assay", "1473": "strain-specific HI titer", "1474": "An AAV expressing an HA antigen", "1475": "serum antibodies", "1476": "serum antibodies", "1477": "as a nasal spray", "1478": "the same three or four influenza virus strains", "1480": "do not replicate effectively at core body temperature", "1481": "live attenuated influenza vaccine", "1482": "in the mucosa of the nasopharynx", "1483": "induces serum antibody responses, mucosal antibody responses (IgA), and T cell responses", "1484": "specific antibody responses to the HA, and to a lesser extent NA proteins", "1485": "", "1486": "February", "1487": "generally considered to be as effective as inactivated vaccines", "1488": "antigenic match", "1489": "same schedule", "1490": "diversity of the immune response", "1491": "improved understanding of immunity to conserved influenza virus antigens", "1492": "allow ready manipulation and modification of the vector genome", "1493": "allow ready manipulation and modification of the vector genome", "1494": "allow ready manipulation and modification of the vector genome", "1495": "preexisting immunity", "1496": "preexisting immunity", "1497": "53", "1498": "", "1501": "Adenovirus 5", "1503": "having been tested for gene delivery and anti-cancer agents", "1505": "their genome is very stable", "1506": "Adenovirus vectors are attractive as vaccine vectors because their genome is very stable", "1507": "their genome is very stable", "1508": "their genome is very stable", "1509": "their genome is very stable", "1512": "induction of mucosal immunity", "1516": "potent CD8 + T cell and serum antibody responses", "1524": "", "1526": "The vaccine was well tolerated", "1530": "rAd5 vaccines expressing these antigens have been shown to protect against pH1N1 and H5N1 challenges", "1531": "", "1535": "", "1540": "potent cellular and humoral immune responses", "1543": "improve immunogenicity", "1544": "", "1579": "Autographa californica nuclear polyhedrosis virus (AcNPV) expressing the HA of PR8 under control of the CAG promoter (AcCAG-HA)", "1549": "potential for preexisting immunity", "1550": "adenovirus serotypes", "1551": "swine influenza", "1553": "adenovirus types 3, 7, 11, and 35", "1557": "Prime-boost strategies", "1559": "passive immunity", "1560": "passive immunity", "1561": "passive immunity", "1562": "passive immunity", "1563": "limited studies using AAVs as vaccine vectors for influenza", "1564": "positive-sense, single-stranded RNA viruses of the Togaviridae family", "1565": "Semliki Forest virus (SFV), Sindbis (SIN) virus, Venezuelan equine encephalitis (VEE) virus", "1566": "vaccine vectors", "1567": "vaccine vectors", "1568": "self-replicating nature of the RNA", "1569": "induce potent HA-specific immune response", "1570": "VEE targets antigen-presenting cells in the lymphatic tissues, priming rapid and robust immune responses", "1571": "VEE targets antigen-presenting cells in the lymphatic tissues, priming rapid and robust immune responses", "1572": "candidate vaccines for cytomegalovirus", "1573": "the vaccine was immunogenic, inducing CMV-neutralizing antibody responses and potent T cell responses", "1574": "efficacy of repeated immunization", "1575": "recombinant HA vaccine", "1576": "The vectors can accommodate large gene insertions, show limited cytopathic effect in mammalian cells, and have been shown to infect and express genes of interest in a spectrum of mammalian cells", "1577": "The vectors can accommodate large gene insertions, show limited cytopathic effect in mammalian cells, and have been shown to infect and express genes of interest in a spectrum of mammalian cells", "1578": "Recombinant DNA systems", "1580": "cholera toxin B", "1581": "non-specific protection from subsequent influenza virus infection", "1582": "a single-stranded, negative-sense RNA virus that causes disease in poultry", "1583": "Similar to other RNA viruses", "1584": "well-tolerated", "1585": "well-tolerated", "1586": "well-tolerated", "1587": "high doses delivered intravenously", "1588": "", "1589": "PIV5 has a stable RNA genome and no DNA phase in virus replication cycle", "1590": "robust CD8 + T cell responses", "1636": "use of poxviruses as vectors without preexisting immunity concerns", "1637": "replication-defective vectors", "1638": "these approaches are amenable to expression in any of the viruses vectors described here", "1639": "MVA vaccines are very effective stimulators of both cellular and humoral immunity", "1640": "New York vaccinia virus", "1642": "in chick embryo fibroblasts and Vero cells", "1643": "very attenuated and considered safe for use in humans of all ages", "1644": "preexisting immunity", "1645": "immunization with this vector induces weaker vaccine-specific immune responses", "1646": "veterinary", "1647": "robust anti-H3 serum antibody responses as well as high serum antibody levels to the PIV5 vaccine", "1648": "protect against infection and disease", "1649": "recent ability to probe the virus-host interface through RNA interference approaches", "1650": "for at-risk populations", "1651": "a vectored influenza virus vaccine", "1652": "a vectored influenza virus vaccine", "1653": "readily modified and to express transgenes", "1654": "induce immunity at sites of inductive immunity", "1655": "providing protection against both the influenza virus and NDV infection", "1656": "intrinsic augmentation of immunity", "1175": "Viruses", "1176": "retroviruses", "1177": "ribozymes", "1178": "Mitochondria and chloroplasts", "1179": "Viroids", "1180": "Ribozymes", "1181": "Ribozymes are carriers of information, but do not require coding genes", "1182": "The presence of the replicase enzyme was still necessary", "1183": "reverse transcriptase", "1184": "circular single-stranded RNAs", "1185": "genetic triplet code", "1186": "carriers of information, but do not require coding genes", "236": "85 years and older", "225": "from person-to-person", "226": "Twenty-seven", "227": "March 16", "230": "isolate at home during their illness", "231": "betacoronavirus", "232": "", "233": "recognition, initiation, and acceleration", "234": "acceleration phase", "237": "85 years and older", "238": "rRT-PCR", "235": "bats", "228": "Does the patient have recent travel from an affected area?", "244": "severe acute respiratory virus 2", "245": "December 2019", "246": "Wuhan, China", "247": "daily air travel volume", "272": "\u22486 days", "239": "Pre-proof", "240": "", "241": "can play a role in both diagnosing and categorizing\nCOVID-19", "242": "N95", "243": "1 mm", "1238": "an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response", "1239": "\"an extraordinary event which is determined to constitute a public health risk to other States through the international spread of disease and to potentially require a coordinated international response\"", "1240": "Global Initiative on Sharing All Influenza Data", "1219": "December 2019", "1149": "pneumonia", "1151": "pharyngeal (Ct = 30 + 30) and blood samples", "1160": "positively correlated", "1168": "", "1169": "positively", "1171": "high titers", "1170": "positively correlated", "1172": "the virus might replicate in the digestive tract", "1173": "unavailability of convincingly scientific evidence", "1174": "", "2178": "8 August 2014", "2181": "Personal Protective Equipment", "2183": "Spain, USA, and elsewhere", "2184": "connectedness between health professionals, technological devices, and knowledge", "2199": "spherical, enveloped, and the largest of positive-strand RNA viruses", "2200": "birds, farm animals, pets, camels, and bats", "1187": "199", "1188": "2 to 4 February", "1190": "new infections", "1191": "a passenger who started coughing from 19 January 2020 on board", "1192": "1 February", "1193": "199", "1194": "5.0 days", "1196": "greatly reduced the number of infections", "1189": "1373", "1235": "late December 2019", "1236": "63.1 million", "1237": "2.1%", "314": "Protease inhibitor", "315": "infections are typically self-limiting", "308": "viral", "309": "respiratory syncytial virus", "310": "human rhinovirus", "311": "human rhinovirus", "313": "chronic airway inflammation, and a history of respiratory symptoms", "317": "morbid obesity", "319": "two", "320": "haemagglutinin (HA) and the neuraminidase (NA)", "322": "", "323": "H275Y", "324": "difficulty with aerosol delivery, cost and potential harm to healthcare workers", "546": "HFRS", "547": "an enveloped, negative-sense RNA virus", "548": "rodents", "549": "plasma viral load", "551": "as an antiviral medicine", "552": "rs12252 C allele and CC genotype", "554": "IFITM1, 2, and 3", "555": "inhibiting virus entry into the host cells", "556": "rs12252 C allele", "806": "interventions implemented several weeks earlier", "807": "11th March", "808": "", "796": "case isolation", "797": "counterfactual model", "799": "estimated reproduction number Rt", "801": "by calculating backwards from the deaths observed over time to estimate transmission that\noccurred several weeks prior", "803": "intervention\nimpact is the same across countries and time", "810": "2-3 weeks", "811": "local and national Iockdowns", "814": "reduce the effective reproduction number", "815": "", "819": "", "820": "23rd January", "823": "", "827": "", "829": "high proportion of\ninfections not detected by health systems", "837": "back-calculate infections from\nobserved deaths", "839": "5.9 [1.9-15.2] million", "840": "9.8%", "843": "between 1.88% and 11.43%", "844": "Germany", "847": "1.1%", "848": "3.7%", "849": "1.1%", "850": "France 3.0%", "851": "0.72%", "852": "9.8%", "853": "0.41%", "854": "15%", "855": "15%", "856": "3.2%", "857": "United Kingdom 2.7%", "859": "", "862": "It is too early to detect substantial\nintervention impact", "869": "The close spacing of interventions in time", "871": "", "873": "a counterfactual model without the interventions\nand compare this to the actual model", "1071": "encompasses other interventions previously\nimplemented", "1074": "underreporting as well as systematic and country-specific changes in testing", "1076": "", "1078": "isolation if travelling back from an epidemic country", "1079": "Banning of gatherings of more than 5 people", "1080": "banning large gatherings and advising individuals not to socialize outside\ntheir households", "1081": "banning large gatherings and advising individuals not to socialize outside\ntheir households", "1083": "encompasses other interventions previously\nimplemented", "1084": "time from infection to the onset\nof symptoms", "1085": "time from the onset of symptoms to death", "1086": "1%)", "1095": "the initial reproduction number before interventions and the effect sizes from\ninterventions", "1097": "infection to onset of symptoms or infection-\nto-onset", "1098": "infection to onset of symptoms or infection-\nto-onset", "1102": "time from the onset of symptoms to death", "1100": "", "1103": "23.9 days", "1104": "discrete renewal process", "523": "below 2%", "525": "phase 6", "527": "", "528": "$30-$100 billion", "881": "through respiratory tract", "882": "through respiratory tract and then induced pneumonia", "883": "unreliable results", "884": "unreliable results", "885": "qPCR", "886": "viral IgM and IgG serological test", "1057": ":50 million", "1058": "5", "1059": ":50 million", "1060": ":50 million", "1062": "Antigenic similarity\nof influenza A (H1N1) viruses from epidemics in 1977\u20131978 to\n\u201cScandinavian\u201d strains isolated in epidemics of 1950\u20131951.", "1063": "", "1064": "1930s", "1065": "", "1066": "1918", "1068": "", "1070": "None of these Viral descendants, however,\napproaches the pathogenicity", "1072": "", "1073": "2 major descendant lineages of the 1918\nH1N1 Virus, as well as 2 additional reassortant lineages,\npersist naturally", "1075": "Many questions about its\norigins, its unusual epidemiologic features, and the basis of\nits pathogenicity remain unanswered", "1082": "its origin remains puzzling", "1087": "we do not know how", "1088": "high Virulence", "1089": "winter", "1090": "1889, 1847, and even earlier", "1091": "1918", "1092": ">2.5%,", "1093": "fall\nand winter of 191871919", "1094": "exceptional pathogenicity", "1096": "", "1099": "lower environ-\nmental temperatures and human nasal temperatures", "1101": "cannot", "1105": "H1N1 Viruses", "1106": "unknown", "1107": "Novel origin", "1108": "little antigenic change", "1109": "5 to 14\nyears of age", "1110": "unusually\nyoung", "1111": "5 to 14\nyears of age", "1112": "33,34", "1113": "a \u201cW\u2014shaped\u201d curve", "1114": "similarities", "1117": "modern antiviral and antibacterial drugs,\nvaccines, and prevention knowledge", "1120": "sequential waves seen\nin individual countries were typically compressed into\nz879 months", "1123": "The Viral genotypic\nbasis of this pathogenicity is not yet mapped", "1872": "exponential growth pattern", "1875": "unreported cases", "1877": "basic reproduction number", "1879": "21-fold", "1880": "2.56", "1881": "between 1 and 15 January 2020", "1882": "Wuhan, China", "1884": "fever, cough, and shortness of breath", "1886": "41", "1889": "2066 (618 of them are in Wuhan) confirmed cases and 56 (45 of them were in Wuhan) deaths in mainland China", "1891": "", "1892": "4000", "1893": "Wuhan Municipal Health Commission", "1894": "National Health Commission of China", "1895": "exponential growing mechanistic in the early outbreak", "1907": "as an exponential growing Poisson process", "529": "Global Initiative on Sharing All Influ", "531": "E and RdRp", "266": "negative progression and adverse outcomes", "267": "smokers are twice more likely", "2185": "limited information available regarding incubation time, transmissibility, and virus origin", "2186": "", "2187": "", "2188": "January 24, 2020", "2189": "Chicago", "2190": "January 30, 2020", "2191": "", "2192": "", "2193": "Fever and cough", "2194": "non-specific symptoms resembling that of influenza", "2195": "patients with underlying medical conditions and the elderly", "2196": "", "2197": "through contact with infected respiratory secretions", "2198": "thought to be low", "1909": "Over 168 million", "1910": "those in complex humanitarian crises", "1911": "Poor governance, public distrust, and political violence", "1912": "Populations affected by humanitarian crises", "1913": "displacement, crowded housing, malnutrition, inadequate water, sanitation, and hygiene (WASH) tools, and stigmatization", "1914": "reduce access to limited healthcare", "1915": "limited public health, laboratory, and primary care services", "1916": "well-known pathogens in humanitarian settings", "1917": "Frequent displacement and limited contact information", "1918": "overcrowding", "1919": "humanitarian crises", "1920": "protect healthcare workers", "1921": "", "1922": "", "1923": "distribution of soap to households in humanitarian settings", "1924": "rights to dignity", "1925": "Widespread introduction of alcohol-based hand rubs", "1926": "The Sphere Handbook", "1927": "reducing both bacterial and viral pathogen transmission", "1928": "evidence pertaining to the prevention of illnesses transmitted by the faecal-oral route", "1929": "latrines in crisis settings are often shared and distant from residential shelters", "1930": "accessing latrine-adjacent handwashing stations", "1931": "Crisis-affected community engagement", "1932": "mitigation plans will fall short of health and human rights obligations in outbreak response", "1933": "Transparent and credible information-sharing mechanisms", "1934": "Diplomacy bridging long-standing mistrust of public health and biomedical interventions and facilitating engagement with contentious actors", "259": "between 21 and 25 million", "286": "starvation, cold, and poor living conditions", "291": "almost had nothing in their hands to help individuals who were infected by influenza viruses", "295": "Tylenol or Advil", "297": "0.56/100,000", "299": "We do not have a universal vaccine to prevent all influenza virus infections", "300": "0.0094-0.0147%", "301": "we travel faster, and we travel more frequently and globally, and we have more complicated social activities and lifestyles", "302": "increased population health and immunity", "303": "32", "304": "Only those who have very severe flu-like symptoms would see doctors"}